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Evren Ozdemir, Kiymet Akgedik, Sadiye Akdogan, Emin KansuNausea and vomiting during the infusion of cryopreserved peripheral blood stem cells (PBSC) are common.
The aimof this studywas to explore the effect of lollipopwith strawberry aromaon the infusion-related nausea
and vomiting of cryopreserved autologous PBSCs. We compared 2 groups of adult patients receiving lollipop
with strawberry aroma during cryopreserved PBSC infusions or not to assess the incidences of nausea and
vomiting occurring during infusions. All patients received granisetron 3 mg i.v. twice a day, and lorazepam 1
mg every 4 hours orally for prophylaxis of the nausea and vomiting during conditioning phase and infusion
day. Before infusion, all patients were premedicated with pheniramine maleate 45.5 mg i.v. and paracetamol
500 mg orally. The patients had no evidence of nausea or vomiting prior to cryopreserved PBSC infusions.
The patients with ongoing nausea or vomiting owing to conditioning regimens and/or receiving additional an-
tiemetics were excluded from the study. One hundred fifty-eight patients who consecutively underwent autol-
ogous stem cell transplantation for malignancy were included in the study. The first 110 patients (median age:
42.5, range: 17-75) were observed for the infusion related adverse effects only. The consecutive 48 patients
(median age: 48, range: 18-80) were given a lollipop with strawberry aroma during cryopreserved PBSC
infusions and observed for the infusion-related adverse effects. The 2 groups were comparable with respect
to age, sex, diagnosis, stem cell collection methods, conditioning regimens administered, total mononuclear
cell dose infused, number of total nucleated cells (TNCs) infused, number of CD341 cells infused, number
of bags infused, total volume infused, amount of dimethylsulfoxide (DMSO), and infusion rate. Patients who
received a lollipop with a strawberry aroma during infusions had significantly less nausea (6.3%, n 5 3 versus
21.8%, n5 24, P5.02) and vomiting (2%, n5 1 versus 13.6%, n5 15, P5.04) than the ones who did not (ob-
servation only group).Other infusion-related adverse eventswere as follows; hypoxia, cough, dyspnea, abdom-
inal cramping, tachycardia, hiccup, fever, chills, chest pain, hypotension, hypertension, agitation, sore throat, and
arrhythmia. Incidencesof eachof these adverse eventswere\5% in both groups andwere comparable. The use
of a lollipop with a strawberry aroma during infusion of cryopreserved autologous PBSCs may be promising in
reduction of infusion-related nausea and vomiting, with an easy administration at a very cheap cost.
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Infusion-related toxicities of cryopreserved au-
tologous peripheral stem cells (PBSC) are common
[1-5]. Adverse events (AE), of either cardiovascular or non-
cardiovascular type, canoccur after infusionof cryopreserved
PBSCcontainingdımethylsulfoxıde (DMSO)andaremostly
attributed to the amount of DMSO infused. Among these
AEs, nausea, vomiting, dyspnea, hypertension, hypotension,
bradycardia, abdominal cramping, flushing, headache, fever,
chills, andchest tightness are themost reportedones [1-5]. In
some series, an overall incidence of noncardiovascular AEs
was up to 70% [1-3].1425
Table 1. Characteristics of the Study Subjects
Lollipop with Strawberry Aroma
during Cryopreserved PBSC Infusion
Yes No P
N (%) 48 (30.4%) 110 (69.4%)
Age (median, range) 48 (18-80) 42.5 (17-75) .074
Gender
Female 17 (35.4%) 45 (40.9%) .59
Male 31 (64.6%) 65 (59.1%)
Diagnosis
Multiple myeloma 20 (41.7%) 31 (28.2%) .18
Hodgkin’s lymphoma 11 (22.9%) 24 (21.8%)
Non-Hodgkin’s lymphoma 11 (22.9%) 44 (40.0%)
Others 6 (12.5%) 11 (10.0%)
Stem cell collection method
Filgrastim only 20 (41.7%) 31 (28.2%) .1
HD cyclophosphamide
followed by filgrastim
28 (58.3%) 79 (71.8%)
Conditioning Regimens
Mitoxantrone-Melphalan 24 (50.0%) 72 (65.5%) .18
Melphalan 20 (41.7%) 31 (28.2%)
Carboplatin-Melphalan 4 (8.3%) 7 (6.3%)
MNCs infused (x1010/kg)
(median, range)
4.6 (1.8-13.4) 4.4 (0.8-19) .49
TNCs infused (x108/kg)
(median, range)
6.4 (2.5-21.6) 6.15 (2.0-21.0) .65
CD34+ cells infused
(x106/kg) (median, range)
8.2 (2.3-24.3) 6.8 (2-28) .08
Patient weight (kg)
(median, range)
73.5 (47-113) 70 (39-98) .29
No of bags (aliquotes) infused
>2 41 (85.4%) 99 (90.0%) .42
2 7 (14.6%) 11 (10.0%)
Nausea
Yes 3 (6.3%) 24 (21.8%) .02
No 45 (93.7%) 86 (78.2%)
Vomiting
Yes 1 (2%) 15 (13.6%) .04
No 47 (98%) 95 (86.4%)
HD indicates high dose; TNCs, total nucleated cells; MNCs, mononucle-
ated cells.
1426 Biol Blood Marrow Transplant 14:1425-1428, 2008E. Ozdemir et al.Cryopreservationof stemcells after collection from
peripheral blood or bonemarrow for autologous trans-
plantation necessitates protectionwithDMSOto allow
for the storage of collected cells in a viable condition for
a prolonged period. DMSO is the most widely used
cryoprotectant in the preservation of PBSCs. It offers
cryopreservation of cell function by crossing the cell
membrane rapidly to stabilize the cell throughout the
freezing process. Unfortunately,DMSO,when infused
with the thawed cell suspension, may induce some
complications and side effects. Among these, nausea
and vomiting are probably the most frequent AEs ob-
served [1-5]. Because DMSO has great ability to cross
tissue membranes, it is rapidly absorbed from the skin
and mucosal surfaces of the body. A noxious, garlic-
like taste and odor occurs in patients’ mouth and on
their tongues within minutes of DMSO administra-
tion, and may last for several hours. The taste and
odor are associated with the metabolites of DMSO. A
small proportion of the infused DMSO is reduced to
dimethyl sulfide (DMS), which is excreted through
the skin, breath, feces, and urine for approximately 24
to 48 hours after administration. This excreted DMS
is the product responsible for the characteristic mal-
odor described as a ‘‘noxious, garlic-like odor’’ [6-8].
The stimuli of odor and taste is received by the
peripheral receptors and carried through the olfactory
nerve and gustatory branches of facial, glossopharyng-
eal, and vagal cranial nerve pathways to the central
olfactory and taste pathways including the limbic and
hypothalamic neural system [9]. It may be the involve-
ment of the limbic and hypothalamic neural system in
the processing of odor and taste that leads to a complex
reaction involving many aspects of cognition and
emotion [10]. A range of olfactory and gustatory sen-
sory stimuli can cause a variety of complex psychophys-
iologic responses such as profound childhood
memories, an awareness of danger, and nausea and
vomiting [11]. Therefore, it is likely that malodor and
taste caused by DMSO metabolites affect the central
limbic-hypothalamic pathways triggering nausea and
vomiting.
We set out with this study to explore the effect of
lollipop with strawberry aroma on the infusion-related
nausea and vomiting of cryopreserved autologous
PBSCs.METHODS
Patients
We evaluated the infusion-related nausea and
vomiting of cryopreserved autologous PBSCs trans-
planted in 158 consecutive adult patients receiving
high-dose (HD) chemotherapy and stem cell trans-
plantation for malignancy at our institution. The first
110 patients were observed for the infusion relatedAEs only and were not given a lollipop during infu-
sions. The consecutive 48 patients were allowed to
suck a lollipop with a strawberry aroma on their
tongues and buccal mucosa during infusions and ob-
served for the infusion-related AEs. These patients
started sucking lollipops right before infusions began
and continued to suck lollipops throughout all infu-
sions until the end of the last bag infused. We com-
pared these 2 groups of adult patients receiving
a lollipop with a strawberry aroma during cryopre-
served PBCS infusions or not to assess the incidences
of nausea and vomiting occurring during infusions
among each group. The characteristics of the patients
and HD chemotherapy schedules employed are shown
in Table 1. The patients had no evidence of nausea or
vomiting prior to cryopreserved PBSC infusions. The
patients with ongoing nausea or vomiting owing to
conditioning regimens and/or receiving additional
antiemetics were excluded from the study. All
patients gave an informed consent to participate in
the study.
Table 2. Other Adverse Effects Observed
Lollipop with Strawberry Aroma
during Cryopreserved PBSC Infusion
Yes No P
N (%) 48 (30.4%) 110 (69.4%)
Hypoxia 2 (%4.1) 4 (%3.6) NS
Cough 2 (%4.1) 4 (%3.6) NS
Dyspnea 1 (%2) 3 (%2.7) NS
Abdominal cramping 1 (%2) 3 (%2.7) NS
Tachycardia 0 (%0) 3 (%2.7) NS
Hiccup 1 (%2) 2 (%1.8) NS
Fever 1 (%2) 2 (%1.8) NS
Chills 1 (%2) 2 (%1.8) NS
Chest pain 1 (%2) 2 (%1.8) NS
Hypotension 0 (%0) 2 (%1.8) NS
Hypertension 0 (%0) 2 (%1.8) NS
Agitation 0 (%0) 2 (%1.8) NS
Sore throat 0 (%0) 2 (%1.8) NS
Arrhythmia 0 (%0) 1 (%1) NS
PBSC indicates peripheral blood stem cells.
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Stem Cell InfusionApheresis and Cryopreservation
In all cases, the hematopoietic cell (HPC) source
was PBSC harvested by apheresis using a CS-3000
blood cell seperator. PBSCs were collected following
mobilization with filgrastim alone for all myeloma
patients or following HD cyclophosphamide (Cy) for
the rest of the patients (Table 1). Cell suspensions
were cryopreserved in 10% DMSO and autologous
plasma, in aliquots of 60 mL (fixed volume). The
maximum cellular concentration in suspensions was
1  108/mL. Total mononuclear cell dose, number
of total nucleated cells (TNCs), and number of CD341
cells were calculated before freezing. Cryopreservation
was performed with a controlled rate of freezing, and
aliquots were stored in liquid nitrogen.
Thawing and Infusion
HPCs were thawed and infused 24 hours after
completion of HD chemotherapy. All patients re-
ceived granisetron 3 mg i.v. twice a day, lorazepam 1
mg every 4 hours orally for prophylaxis of the nausea
and vomiting during conditioning phase and infusion
day. Before infusion, all patients were premedicated
with pheniramine maleate 45.5 mg i.v. and paraceta-
mol 500 mg orally. The cryopreserved aliquots
(bags) were rapidly thawed, and each bag was immedi-
ately infused without further manipulation within 5 to
10 minutes.
Data Collection and Statistical Analyses
Data on occurrence of AEs were collected prospec-
tively. Type (fever, chills, nausea, vomiting, abdominal
cramping, tachycardia, bradycardia, hypertension, hy-
potension, sore throat, chest pain, cough, and dyspnea)
and number of AEs occurring at each infusion were re-
corded using a specifically designed worksheet. AEs
were graded using NCI-CTC. In all cases, infusions,
observation, and care of the patients during infusions
were performed by the primary care physician.
Statistical analyseswereperformedusingPrismSta-
tistical Software (Graphpad, SanDiego,CA) onMacin-
tosh computers (Apple Computer, Cupertino, CA).
Intergroup comparisons were performed using the
t-test and the Mann-Whitney U-test for univariate
parametric and nonparametric group analyses, respec-
tively.Distribution of categoric variableswas compared
using a chi-square-test and Fisher’s exact test. All P
values were 2-tailed and considered significant if\.05.RESULTS
Patients Characteristics
Forty-eight patients (median age: 48, range: 18-80)
were given a lollipop with a strawberry aroma during
cryopreserved PBSC infusions and 110 (median age:42.5, range: 17-75) were not (observation only group).
The 2 groups were comparable with respect to age, sex,
diagnosis, stem cell collection methods, conditioning
regimens administered, total mononuclear cell dose
infused, number of TNCs infused, number of
CD341 cells infused, and number of bags (Table 1).
The number of bags accurately reflects the volume
and amount of DMSO infused, because we used a fixed
volume (60 mL) of aliquots and each bag contained the
same volume and amount of DMSO. Infusion rate was
similar in both groups and each bag was infused after
thawing within 5 to 10 minutes. Patients receiving
a lollipop were slightly older (P 5 .074).The Lollipop with a Strawberry Aroma Reduces
Infusion-Related Nausea and Vomiting during
the Infusion of Cryopreserved PBSCs
Patients who received a lollipop with a strawberry
aroma during infusions had significantly less nausea
(6.3%, n5 3 versus 21.8%, n5 24, P5 .02) and vom-
iting (2%, n 5 1 versus 13.6%, n 5 15, P 5.04) than
the ones who did not (observation only group) (Table
1). All nausea and vomiting episodes were grade I-II
according to the NCI-CTC.
Other infusion-related adverse events were as fol-
lows; hypoxia, cough, dyspnea, abdominal cramping,
tachycardia, hiccup, fever, chills, chest pain, hypoten-
sion, hypertension, agitation, sore throat and arrhyth-
mia (Table 2). Incidences of each of these adverse
events were\5% in both groups and were comparable
(Table 2). All AEs were grade I-II according to the
NCI-CTC, except 2 patients each in both groups
had grade III hypoxia necessitating bronchodilator
and oxygen treatment. One patient in the observation
only group had grade I premature ventricular com-
plexes (PVCs) that disappeared after infusion without
intervention.
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Infusion of cryopreserved PBSC containing
DMSOmay trigger nausea and vomiting, likely owing
to the malodor and taste caused by DMSO metabo-
lites. In this study, we have chosen a lollipop with
a strawberry aroma and allowed a group of patients
to suck this lollipop on their tongues and buccal mu-
cosa during infusions in an attempt to mask the nox-
ious taste and odor associated with the metobolites
of DMSO. Our findings show that this approach
may reduce infusion-related nausea and vomiting.
We think that a pleasant taste and odor owing to the
lollipop with strawberry aroma replaces or masks the
taste and malodor produced by DMSO metabolites,
thus decreasing physical symptoms of nausea and
vomiting. Moreover, it is also very easy to administer
at very cheap cost compared to the other preventive
methods such as depletion of DMSO before auto-
grafting.
Adverse events after HPC infusion have tradi-
tionally been associated with the amount of infused
cryoprotectant, DMSO [2-4,12]. Gastrointestinal
side effects appear to be strictly related to the number
of bags reinfused, probably reflecting on the amount of
DMSO infused [3,12] and to speed of reinfusion [12].
Noncardiovascular AEs may also be dependent on
patient age [13]. In our study, study groups were com-
parable with respect to age, number of TNCs infused,
number of bags (aliquots) infused, amount of DMSO,
and infusion rate. Therefore, the effects of such factors
on the study outcome is unlikely.
Depletion of DMSO before autografting is an-
other method to decrease the DMSO amount infused,
andmay cause less complications and side effects; how-
ever, the procedure is cumbersome, takes 3 to 4 hours
of laboratory work per patient, and may have a poten-
tial for PBSC loss during the procedure [14,15].
In conclusion, the use of a lollipop with a straw-
berry aroma during infusion of cryopreserved autolo-
gous PBSCs may be promising in reduction of
infusion-related nausea and vomiting with an easy
administration at a very cheap cost. However, our
findings need to be tested in a larger randomized trial
for a definitive conclusion. A prospective randomized
study comparing the effects of lollipops with differ-
ent aroma on the infusion-related nausea and vomit-ing of cryopreserved PBSCs is underway at our
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